All In Biotech

Drug Trial Radar · NCT07219615

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

A PHASE 2B RANDOMIZED, DOUBLE-BLIND, 12-WEEK PLACEBO-CONTROLLED STUDY WITH A 12-WEEK DOUBLE-BLIND EXTENSION PERIOD TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH CHRONIC SPONTANEOUS URTICARIA

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 30, 2025

Primary completion

Dec 25, 2026

Study completion Apr 23, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are used to stop the body's "allergy alarm system" from overreacting. Chronic spontaneous urticaria is a disease that causes itchy hives and swellings in the deep layers of skin and fatty tissue just underneath the skin that come and go without a clear reason. This study will look at both the 50 milligrams (mg) once daily (QD) oral dose and 100 milligrams (mg) once daily (QD) oral dose and compare them to placebo (pill with no active medicine). This study is seeking participants who: * Are 18 years of age or older * Have a diagnosis of chronic spontaneous urticaria for 3 months or more that has not been controlled well with antihistamine treatment. * Do not have any other skin conditions associated with chronic itching or itching caused mainly by known triggers. * Are willing to stop all other treatments that they may be taking for chronic spontaneous urticaria other than a second-generation antihistamine (sgAH). About 150 participants will take part in this study. Participants will be chosen by chance, like drawing names out of a hat, to receive either the 50 mg dose or 100 mg dose or placebo, taken by mouth once daily for 12 weeks( Period A). Thereafter the participants on 50 mg and 100 mg will continue on their doses while the participants receiving placebo will be switched to 100mg for an additional 12 weeks (Period B). The 2 doses of ritlecitinib in this study will be compared to each other and to the placebo. This will help to see if the 50 mg and/or 100 mg dose of ritlecitinib is safe and effective. Participants will be in this study for about 8 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as: * Physical examinations, * Hearing tests, * Blood tests, * X-ray, * ECG (electrocardiogram), * Participants will also be asked to complete questionnaires every day about their chronic spontaneous urticaria in an electronic diary.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • Ritlecitinib 50 mgDrug

    50 mg Capsule

  • Ritlecitinib 100 mgDrug

    100 mg Capsule

  • Placebo - 50 mgDrug

    Matching Capsule

  • Placebo - 100 mgDrug

    Matching Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Urticaria Activity Score 7 (UAS7) at Week 12Time frame: Week 12
  2. Incidence of Treatment Emergent Adverse Events, Serious Adverse Events, and Adverse Events leading to discontinuationTime frame: Week 12

Locations

77 sites in 10 countries. Site status is shown where the registry gives one.

  • Saguaro Dermatology - Phoenix

    Phoenix, Arizona · Recruiting

  • Acuro Research, Inc.

    Little Rock, Arkansas · Recruiting

  • Kern Research, Inc.

    Bakersfield, California · Recruiting

  • First OC Dermatology Research Inc

    Fountain Valley, California · Recruiting

  • Antelope Valley Clinical Trials

    Lancaster, California · Recruiting

  • Ark Clinical Research

    Long Beach, California · Recruiting

  • Skin & Beauty Center - Pasadena

    Pasadena, California · Recruiting

  • Asthma and Allergy Associates, PC

    Colorado Springs, Colorado · Recruiting

  • Asthma and Allergy Center of Chicago

    River Forest, Illinois · Recruiting

  • Chesapeake Clinical Research

    White Marsh, Maryland · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Revival Research Institute, LLC

    Troy, Michigan · Recruiting

  • Equity Medical, LLC

    The Bronx, New York · Recruiting

  • Allergy, Asthma, & Clinical Research Center

    Oklahoma City, Oklahoma · Recruiting

  • Vital Prospects Clinical Research Institute, PC

    Tulsa, Oklahoma · Recruiting

  • Columbia Dermatology & Aesthetics

    Columbia, South Carolina · Recruiting

  • Orion Clinical Research

    Austin, Texas · Recruiting

  • RFSA Dermatology - San Antonio - West Avenue

    San Antonio, Texas · Recruiting

  • Complete Dermatology

    Sugar Land, Texas · Recruiting

  • Medical Center Pulmo - 2018 EOOD

    Haskovo, Bulgaria · Recruiting

  • Diagnostic Consultative Center 1 - Pernik

    Pernik, Bulgaria · Recruiting

  • Diagnostic Consultative Center "Ascendent"

    Sofia, Bulgaria · Recruiting

  • Medical Center Hera EOOD

    Sofia, Bulgaria · Recruiting

  • Medical Center Pulmovision

    Sofia, Bulgaria · Recruiting

  • Diagnostic Consultative Center Aleksandrovska

    Sofia, Sofia (stolitsa), Bulgaria · Recruiting

  • Centre de Recherche Saint-Louis inc.

    Québec, Canada · Recruiting

  • Laser Rejuvenation Clinics Edmonton D.T. Inc

    Edmonton, Alberta, Canada · Recruiting

  • CaRe Clinic

    Red Deer, Alberta, Canada · Recruiting

  • Allergy Centre Research

    Mississauga, Ontario, Canada · Recruiting

  • Allergy Research Canada Inc.

    Niagara Falls, Ontario, Canada · Recruiting

  • DAR Clinical Research

    Ottawa, Ontario, Canada · Recruiting

  • Dar Clinical Research

    Ottawa, Ontario, Canada · Recruiting

  • Research Institute of the McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • The Third Affiliated Hospital Of Sun Yat-Sen University

    Guangzhou, Guangdong, China · Recruiting

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First People's Hospital of Hangzhou

    Hangzhou, Zhejiang, China · Recruiting

  • Charite Universitätsmedizin Berlin Campus Benjamin Franklin

    Berlin, Germany · Recruiting

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.